Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences
Myriad Genetics (MYGN) announced that its management will participate in fireside chats at three upcoming healthcare investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Myriad Genetics (MYGN) announced that its management will participate in fireside chats at three upcoming healthcare investor conferences.
The schedule includes UBS Global Healthcare on November 10, 2026, at 1:15 pm ET; Stephens Investment on November 18, 2026, at 3:00 pm ET; and Piper Sandler Healthcare on December 2, 2026, at 12:30 pm ET. Live audio webcasts will be available at investor.myriad.com.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that Myriad management will participate in three upcoming healthcare conferences.
- The UBS Global Healthcare Conference with a fireside chat on Tuesday, Nov. 10, 2026, at 1:15 pm ET.
- The 2026 Stephens Investment Conference with a fireside chat on Wednesday, Nov. 18, 2026, at 3:00 pm ET.
- The 38th Annual Piper Sandler Healthcare Conference with a fireside chat on Wednesday, Dec. 2, 2026, at 12:30 pm ET.
The presentations will be available through live audio webcast links in the investor information section of Myriad’s website at investor.myriad.com.
About Myriad Genetics
Myriad Genetics is a leading molecular diagnostic and precision medicine company committed to advancing health and well-being for all. Myriad Genetics develops and commercializes molecular tests that help patients and providers uncover genetic insights. Our tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care, support earlier detection, enable more precise treatment and contribute to lowering healthcare costs. For more information, visit www.myriad.com.
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
Media Contact
Andria Rosell
(385) 202-3510
PR@myriad.com
